Santos, S.Malheiro, J.Tafulo, S.Dias, L.Carmo, R.Sampaio, S.Costa, M.Campos, A.Pedroso, S.Almeida, M.Martins, L.Henriques, C.Cabrita, A.2017-07-242017-07-242016-12-24World J Transplant. 2016 Dec 24;6(4):689-6962220-3230http://hdl.handle.net/10400.16/2161AIM: To analyze the clinical impact of preformed antiHLA-Cw vs antiHLA-A and/or -B donor-specific antibodies (DSA) in kidney transplantation. METHODS: Retrospective study, comparing 12 patients transplanted with DSA exclusively antiHLA-Cw with 23 patients with preformed DSA antiHLA-A and/or B. RESULTS: One year after transplantation there were no differences in terms of acute rejection between the two groups (3 and 6 cases, respectively in the DSA-Cw and the DSA-A-B groups; P = 1). At one year, eGFR was not significantly different between groups (median 59 mL/min in DSA-Cw group, compared to median 51 mL/min in DSA-A-B group, P = 0.192). Moreover, kidney graft survival was similar between groups at 5-years (100% in DSA-Cw group vs 91% in DSA-A-B group, P = 0.528). The sole independent predictor of antibody mediated rejection (AMR) incidence was DSA strength (HR = 1.07 per 1000 increase in MFI, P = 0.034). AMR was associated with shortened graft survival at 5-years, with 75% and 100% grafts surviving in patients with or without AMR, respectively (Log-rank P = 0.005). CONCLUSION: Our data indicate that DSA-Cw are associated with an identical risk of AMR and impact on graft function in comparison with "classical" class I DSA.engAnti human leukocyte antigen class IAntiHLA-Cw antibodiesAntibody-mediated rejectionDonor-specific antibodiesGraft survivalSolid-phase immunoassaysjournal article10.5500/wjt.v6.i4.689